A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Abroad (travel likely)RecruitingPHASE3

Conditions

Heterozygous Familial Hypercholesterolemia (HeFH)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University First Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Jianping Li, PhD) · lijianping03455@pkufh.com · 010-66119025

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Heterozygous Familial Hypercholesterolemia (HeFH)

Abroad (travel likely)RecruitingPHASE2, PHASE3

Wilmington, United States · Washington D.C., United States

"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)"

Heterozygous Familial Hypercholesterolemia (HeFH)

Abroad (travel likely)Recruiting

Paris, France · Paris, France

The ORIGIN-FH Study

Heterozygous Familial Hypercholesterolemia (HeFH) · Homozygous Familial Hypercholesterolemia (HoFH) · Familial Hypercholesterolemia

Abroad (travel likely)Recruiting

Madison, United States

Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia

Heterozygous Familial Hypercholesterolemia

Abroad (travel likely)Recruiting

Angers, France · Nantes, France